A5024137095- Prostate Cancer Treatment and Research
- Protein Degradation and Inhibitors
- Hormonal and reproductive studies
- Estrogen and related hormone effects
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- Reproductive Biology and Fertility
- Reproductive System and Pregnancy
- Hemophilia Treatment and Research
- Mass Spectrometry Techniques and Applications
- Bryophyte Studies and Records
- Animal Virus Infections Studies
- Spacecraft and Cryogenic Technologies
- Spacecraft Design and Technology
- Peatlands and Wetlands Ecology
- Satellite Communication Systems
Arvinas (United States)
2017-2024
Infosys (India)
2008
Louisiana State University
1997
Louisiana State University Agricultural Center
1994
259 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during transition from a localized to metastatic disease. Most patients initially respond inhibitors AR pathway, but response is often relatively short-lived. majority progressing on enzalutamide or abiraterone exhibit genetic alterations in locus, either form amplifications point mutations gene. Given these mechanisms resistance, our goal eliminate protein using PROteolysis...
Abstract Prostate cancer is the second leading cause of death in men United States. The androgen receptor (AR) plays critical roles both early disease and advanced prostate cancer. Current therapeutic approaches targeting androgen/AR axis are initially effective, but castration resistant (CRPC) inevitably develops. CRPC tightly linked with increased AR activity via gene overexpression, amplification, gain-of-function mutations. To address these mechanisms AR-dependent tumor growth, we have...
<div>Abstract<p>Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone enzalutamide) are standard treatments for metastatic hormone-sensitive cancer castration-resistant cancer. However, continual evolution during progression can result in <i>AR</i> alterations mutation, amplification, splicing) cause tumors to become resistant these therapies. Bavdegalutamide (ARV-110) a PROteolysis TArgeting...
Abstract The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during transition from a localized to metastatic disease. Most patients initially respond inhibitors AR pathway, but response is often short-lived. majority progressing on enzalutamide or abiraterone exhibit genetic alterations in locus, either form amplifications point mutations gene. Given these mechanisms resistance, our goal eliminate protein using PROteolysis TArgeting Chimera...
Abstract Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone enzalutamide) are standard treatments for metastatic hormone-sensitive cancer castration-resistant cancer. However, continual evolution during progression can result in AR alterations mutation, amplification, splicing) cause tumors to become resistant these therapies. Bavdegalutamide (ARV-110) a PROteolysis TArgeting Chimera (PROTAC) protein degrader...
<p>Supplementary Figure S2 shows the effect of bavdegalutamide on neomorphic substrates</p>
<p>Supplementary Figure S3 shows the effect of bavdegalutamide on SALL4</p>
<p>Supplementary Figure S4 shows maintenance of animal body weights during treatment with bavdegalutamide or enzalutamide in prostate cancer mouse models</p>
<p>Supplementary Figure S1 shows the effect of bavdegalutamide on AR versus AR-V7</p>
273 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during transition from a localized to metastatic disease. Most patients initially respond inhibitors AR pathway, but response is often short-lived. majority progressing on enzalutamide or abiraterone exhibit genetic alterations in locus, either form amplifications point mutations gene. Given these mechanisms resistance, our goal eliminate protein using PROteolysis TArgeting Chimera...
381 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during transition from a localized to metastatic disease. Most patients initially respond inhibitors AR pathway, but response is often short-lived. majority progressing on enzalutamide or abiraterone exhibit genetic alterations in locus, either form amplifications point mutations gene. Given these mechanisms resistance, our goal eliminate protein using PROteolysis TArgeting Chimera...
To evaluate the effects of sequential, repetitive freezing on their in-vitro development, mouse embryos at eight- to 16-cell stage were subjected one five treatments. They (i) cultured as unfrozen controls, (ii) frozen once and cultured, (iii) two consecutive freeze-thaw cycles, (iv) thawed, then for 18-30 h before being a second time, (v) three times in succession without cultured. assess functional survival after thawing, all vitro hatched blastocyst Whitten's medium. In experiment, that...
DOD has identified the assured use of space as a key priority, known Responsive Space. Space requires design and assembly small tactical satellites in greatly reduced timeframes. This capability could be achieved with generic plug-n-play satellite bus implementing modular structural, electronic thermal interfaces for payload supporting components. Modular are particularly difficult to implement, due wide range characteristics To address this need, Infoscitex is developing Variable Thermal...
Abstract The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during transition from a localized to metastatic disease. Most patients initially respond inhibitors AR pathway, but response is often short-lived. majority progressing on enzalutamide or abiraterone exhibit genetic alterations in locus, either form amplifications point mutations gene. Given these mechanisms resistance, our goal eliminate protein using PROteolysis TArgeting Chimera...